CA
RXRX icon

Clearstead Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Clearstead Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– -$1.64K – 2750
2025
Q4 		– Hold
0
– – – 2168
2025
Q3 		– Sell
-5,338
Closed -$28K – 1983
2025
Q2 		$29K Buy
+5,338
New +$26.2K ﹤0.01% 1474
2025
Q1 		– Hold
0
– – – 1279
2024
Q4 		– Sell
-500
Closed -$3.36K – 1236
2024
Q3 		$3.29K Buy
+500
New +$3.58K ﹤0.01% 1772

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearstead Advisors's RXRX Position: Q1 2026 in Review

Clearstead Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 1,479 shares — an estimated $6.05K sold.

Clearstead Advisors first reported a position in RXRX in Q3 2023 and held it in 5 quarters. The position peaked at $6.05K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Clearstead Advisors reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Clearstead Advisors sold 1,479 Recursion Pharmaceuticals shares in Q1 2026, an estimated $6.05K.
  • Clearstead Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Clearstead Advisors's Recursion Pharmaceuticals position peaked at $6.05K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.